Frank Torti Named Acting FDA Commissioner
On January 20, FDA Commissioner Andrew von Eschenback, MD, will step down as commissioner and Frank Torti, MD, will take over as acting commissioner.
On January 20, FDA Commissioner Andrew von Eschenback, MD, will step down as commissioner and Frank Torti, MD, will take over as acting commissioner.
Torti has been the principal deputy commissioner and chief scientist at the FDA since May 2008.
Torti received his BA and MA degrees from Johns Hopkins University, his MD from Harvard Medical School, and his MPH from the Harvard School of Public Health, where he trained in cancer epidemiology and nutrition. He joined Wake Forest University School of Medicine in 1993 as the Charles L. Spurr professor of Medicine, director of the Comprehensive Cancer Center, and chair of the Department of Cancer Biology.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
